| Name | Title | Contact Details |
|---|
CiVi Biopharma Inc. is a US-based, privately-held biopharmaceutical company, founded in 2016. The Company`s research and development activities are focused on creating novel therapies for cardiovascular, metabolic and related diseases. CiVi`s innovative pipeline includes CiVi007, a long-acting PCSK9 third-generation Locked Nucleic Acid antisense molecule being developed for the treatment of hypercholesterolemia and the prevention of cardiovascular disease. In addition, the Company currently has other clinical stage development program activity aimed at treating severe liver diseases.
The greatest health threats require more than an all-or-nothing approach. Nano represents a multi-layered set of solutions to usher in a new era in proactive, persistent health protection.
Founded in 2010, Cold Genesys is a privately-held, clinical-stage biopharmaceutical company focused on the research, acquisition and development of novel immunotherapies.
Eikon Therapeutics is a new biopharmaceutical company employing revolutionary technology at the interface of biology, engineering and chemistry to discover novel treatments for life-threatening diseases. Eikon`s discovery platform is built on groundbreaking innovations from its founders (Nobel Prize, 2014), culminating in the creation of microscopes which enable real time, molecular-resolution measurements of protein movement in living cells.
Mosaic`s biopharmaceutical teams turn ideas into reality. We provide experienced biopharma leadership and cross-functional teams to accelerate your protein therapeutic research and development program